月桂醇PCA酯 | 22794-26-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 月桂醇PCA酯
• 中文别名: 5-氧代-L-脯氨酸十二烷基酯
• 英文名称: pyroglutamic acid n-dodecyl ester
• 英文别名: lauryl pyroglutamate；Dodecyl 5-oxo-L-prolinate；dodecyl (2S)-5-oxopyrrolidine-2-carboxylate
• CAS: 22794-26-9
• 化学式: C₁₇H₃₁NO₃
• 分子量: 297.438
• InChiKey: HJXPPCPJEYUQFQ-HNNXBMFYSA-N

物化性质

• 沸点：
  437.8±38.0 °C(Predicted)
• 密度：
  0.990±0.06 g/cm3(Predicted)
• LogP：
  5.05

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  21
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  月桂醇PCA酯 在 4-二甲氨基吡啶 、 二异丁基氢化铝 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-5-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-dodecyl ester
  参考文献：
  名称：

  C-Clycosylation of cyclic N-acyliminium ions with trimethylsilyloxyfuran

  摘要：

  C-glycosylation of 2-methoxy-5-alkoxycarbonyl pyrrolidines with trimethylsilyloxyfuran allows us to obtain the corresponding pyrrolidines contigus to a alpha,beta-unsaturated butyrolactone. Copyright (C) 1996 Published by Elsevier Science Ltd

  DOI：

  10.1016/0040-4039(96)01828-x
• 作为产物：
  描述：

  十二烷醇 、 L-焦谷氨酸 在 对甲苯磺酸 作用下， 以54%的产率得到月桂醇PCA酯
  参考文献：
  名称：

  C-Clycosylation of cyclic N-acyliminium ions with trimethylsilyloxyfuran

  摘要：

  C-glycosylation of 2-methoxy-5-alkoxycarbonyl pyrrolidines with trimethylsilyloxyfuran allows us to obtain the corresponding pyrrolidines contigus to a alpha,beta-unsaturated butyrolactone. Copyright (C) 1996 Published by Elsevier Science Ltd

  DOI：

  10.1016/0040-4039(96)01828-x

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES MONOTERPÈNES
  申请人：NEONC TECHNOLOGIES INC

  公开号：WO2011109635A1

  公开（公告）日：2011-09-09

  The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w) The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w) The purified monoterpene can be used to treat a disease such as cancer The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

  本发明提供了一种用于纯化纯度大约高于98.5%（质量百分比）的单萜或倍半萜的过程。该过程包括将单萜（或倍半萜）衍生化以产生单萜（或倍半萜）衍生物，分离单萜（或倍半萜）衍生物，并从衍生物中释放单萜（或倍半萜）。本发明范围还涵盖了一种含有纯度大约高于98.5%（质量百分比）的单萜（或倍半萜）的药物组合物。纯化的单萜可用于治疗癌症等疾病。目前的单萜（或倍半萜）可以单独使用，也可以与放射线或其他治疗剂（如化疗药物）联合使用。
• Transdermal galantamine delivery system
  申请人：Audett Jay

  公开号：US20070104771A1

  公开（公告）日：2007-05-10

  A transdermal galantamine delivery system to an individual. The system has a high galantamine loading with suitable permeation enhancers to effect therapeutic flux rate. Acrylate polymeric reservoir with the high galantamine and permeation enhancers dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties for multiple-day delivery.

  一个透皮的加兰他敏递送系统，适用于个人。该系统具有高加兰他敏负载量，并配有适当的渗透增强剂以实现治疗通量率。丙烯酸酯聚合物储液池中含有高加兰他敏和渗透增强剂，提供理想的粘附特性和有效的透皮治疗属性，可进行多日递送。
• Transdermal nicotine salt delivery system
  申请人：Gale M. Robert

  公开号：US20070082038A1

  公开（公告）日：2007-04-12

  A transdermal nicotine salt delivery system to an individual. The system has a high nicotine salt loading to effect therapeutic flux rate. Acrylate polymeric drug reservoir with the high nicotine salt dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.

  一种递送尼古丁盐的贴片给个体的系统。该系统具有高浓度的尼古丁盐负荷，以产生治疗性通量速率。丙烯酸酯类药物储液槽中溶解了高浓度的尼古丁盐，提供了理想的粘附特性和有效的经皮治疗性能。
• Process for the enzymatic synthesis of pyroglutamic esters
  申请人：Pascaly Matthias

  公开号：US20060074259A1

  公开（公告）日：2006-04-06

  A process for the preparation of compounds according to the general formula (I), in which R is a hydrocarbon radical of an alcohol, wherein one or more alcohols of the general formula (II) R—OH  (II) in which R is as defined above, are esterified and/or transesterified without using significant amounts of solvents, preferably without solvents, preferably under reduced pressure at temperatures below 100° C. in the presence of enzymes from the class of hydrolases with a compound according to the general formula (III), in which R 1 is either hydrogen or a linear or branched alkyl or alkenyl group having 1 to 3 carbon atoms is provided.

  一种制备通式（I）化合物的方法，其中R是醇的烃基，其中一种或多种通式（II）的醇R-OH（II）中的醇被酯化和/或转酯化，不使用大量溶剂，最好不使用溶剂，在还原压力下，在低于100°C的温度下，在水解酶类的存在下，使用通式（III）化合物，其中R1是氢或具有1至3个碳原子的线性或支链烷基或烯基基团。
• PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES
  申请人：Chen Thomas

  公开号：US20110280860A1

  公开（公告）日：2011-11-17

  The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

  本发明提供了一种纯化单萜或倍半萜的方法，其纯度大于约98.5%（w/w）。该方法包括将单萜（或倍半萜）衍生化以产生单萜（或倍半萜）衍生物，分离单萜（或倍半萜）衍生物，并从衍生物中释放单萜（或倍半萜）。本发明的范围还包括一种制药组合物，其中包括纯度大于约98.5%（w/w）的单萜（或倍半萜）。纯化后的单萜可用于治疗癌症等疾病。本单萜（或倍半萜）可以单独给药，也可以与放射线或其他治疗剂（如化疗剂）联合给药。